Skip to main content
. 2021 Sep 22;6(18):e150453. doi: 10.1172/jci.insight.150453

Figure 4. Kaplan-Meier estimates of progression-free survival and overall survival in patients with metastatic pancreatic ductal adenocarcinoma harboring SWI/SNF complex alterations treated with immunotherapy and without.

Figure 4

(A) The median progression-free survival (PFS) was 9 months in the immunotherapy-treated pancreatic cancer patients with SWI/SNF alterations (blue line) versus 4 months in the patients not receiving immunotherapy (red line) (P = 0.05 by log rank). (B) The median overall survival (OS) was 15 months for the immunotherapy treated pancreatic cancer patients with SWI/SNF alterations (blue line) and 10 months for the patients not receiving immunotherapy (red line) (P = 0.06 by log rank). Tick marks indicate censored data.